After multivariate adjustment, the female patients (HR = 0.56, 95% CI = 0.42-0.47), EGFR mutation (HR = 0.54, 95% CI = 0.42–0.70), FISH + (HR = 0.67, 95% CI = 0.54–0.84), and ECOG PS 0/1 (HR = 0.71, 95% = 0.52–0.95) were confirmed to be statistically significant as favorable factors for longer PFS in NSCLC patients treated with EGFR-TKIs, whereas MET copy number gain (HR = 1.51, 95% CI = 1.07–2.13) was statistically significant predictors of shorter PFS (Table 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.